Professor, Medicine, Georgetown University School of Medicine
Hematology
Dr. Bruce D. Cheson, MD
|
|
Give Review
Bruce Cheson works in the field of Hematology. He over the years received 7 awards: "America's Top Doctors", "CMS Meaningful Use Stage 1 Certification", "America's Top Doctors for Cancer", "Top Doctors:Washington DC Area", "Top Doctors:Washington-Baltimore", "Northern Virginia Magazine" and "Fellow (FASCO)". Bruce Cheson is also a published doctor. He has 78 paper published. The most recent paper is: Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL. He is registered with Medicare and accepts Medicare payments.
Publications
- Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance).
- Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin Lymphoma in the modern era.
- A phase I study of bendamustine, lenalidomide and rituximab in relapsed and refractory Lymphomas.
- Reply to B. Bennani-Baiti et al, H.J.A. Adams et al, E. Laffon et al, and E.A. Hawkes et al.
- Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell Lymphoma subtypes.
- Letter from the editor.
- CALGB 150905 (Alliance): Rituximab broadens the anti-Lymphoma response by activating unlicensed NK cells.
- A phase I study of PRO131921, a novel anti-CD20 monoclonal antibody in patients with relapsed/refractory CD20+ indolent NHL: Correlation between clinical responses and...
- Which Hodgkin's Patients in the Unites States Should Be Treated with BEACOPP?
- Reply to M.C. Chamberlain.
- Current role of FDG PET/CT in Lymphoma.
- How we manage follicular Lymphoma.
- Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Grou...
- Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia.
- A Comparative Analysis of Prognostic Factor Models for Follicular Lymphoma Based on a Phase III Trial of CHOP-Rituximab versus CHOP + 131Iodine--Tositumomab.
- A Summer of Change in Hematologic Malignancies: Highlights in B-Cell Malignancies From the 2013 ASCO, EHA, and ICML Meetings.
- A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular Lymphoma: CALGB 50701.
- The Optimal Management of Follicular Lymphoma: An Evolving Field.
- Complete Response to Brentuximab Vedotin in a Transplant-Naïve Patient With Relapsed CD30-Positive Nodular Lymphocyte-Predominant Hodgkin Lymphoma.
- Therapy for diffuse large B-cell Lymphoma: getting personal.
- Intensive Chemotherapy and Immunotherapy in Patients With Newly Diagnosed Primary CNS Lymphoma: CALGB 50202 (Alliance 50202).
- The current status and future impact of targeted therapies in non-Hodgkin Lymphoma.
- The Plk1 inhibitor BI 2536 in patients with refractory or relapsed non-Hodgkin Lymphoma: a phase I, open-label, single dose-escalation study.
- Safe and effective treatment of aggressive non-hodgkin Lymphoma with rituximab and bendamustine in patients with severe liver impairment.
- PTCL Therapies: A Review of Treatment and Outline of Novel Therapies.
- Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin Lymphoma: correlative analysis from a large North American co-operative group trial.
- Randomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally Extensive and Advanced-Stage Hodgkin Lymphoma: An Intergroup Study Co...
- The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin Lymphoma patients: a comprehensive analysis from the N...
- Phase III Randomized Intergroup Trial of CHOP Plus Rituximab Compared With CHOP Chemotherapy Plus 131Iodine-Tositumomab for Previously Untreated Follicular Non-Hodgkin...
- The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Al...
- Primary Non-Hodgkin's Lymphoma of the Extrahepatic Bile Duct.
- A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell Lymphoma.
- Time To Remember To Forget Dose-Intensification in Lymphoma.
- Histiocytic sarcoma transdifferentiated from follicular Lymphoma presenting as a cutaneous tumor.
- Bortezomib, Bendamustine, and Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma: The Phase II VERTICAL Study.
- Genetic abnormalities in CLL: prognostic factors--or their own Disease?
- Role of functional imaging in the management of Lymphoma.
- Doxorubicin, vinblastine, gemcitabine (CALGB 50203) for stage I/II non-bulky Hodgkin Lymphoma: pretreatment prognostic factors and interim PET.
- Bendamustine produces durable responses with an acceptable safety profile in patients with rituximab-refractory indolent non-Hodgkin Lymphoma.
- Cogan's syndrome.
- Resolution of Lymphoma-associated Open-angle Glaucoma by Rituximab.
- The sarcoid-Lymphoma syndrome.
- Another summer of hematology.
- Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-Cell malignancies.
- Targeted treatment and new agents in follicular Lymphoma.
- Clinical Roundtable Monograph: current treatment options for NHL patients refractory to standard therapy: recent data in single-agent and combination therapy.
- Syk [sic] of the same old chemotherapy?
- Life, liberty, and the pursuit of health care.
- Optimal use of bendamustine in chronic lymphocytic Leukemia, non-Hodgkin lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel.
- Monoclonal antibodies in advanced B-cell Lymphomas.
- Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin Lymphoma: results from a Multicenter Study.
- Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell Lymphoma: CALGB 59909.
- Bendamustine induced neurotoxicity.
- Making the H1N1 (Swine) flu vaccine mandatory for hospital employees.
- New drug development.
- A summer of hematologic science. Highlights from the 45th Annual Meeting of the American Society of Clinical Oncology, the 14th Congress of the European Hematology Ass...
- Expanding our mission: Clinical Lymphoma, Myeloma & Leukemia.
- Outcomes of patients with Burkitt Lymphoma older than age 40 treated with intensive chemotherapeutic regimens.
- I try to be a minimalist in laboratory testing.
- Novel therapies for peripheral T-cell non-Hodgkin's Lymphomas.
- The new and ever changing PhRMA guidelines are impeding productive relationship.
- Etiology and management of tumor lysis syndrome in patients with chronic lymphocytic Leukemia.
- Bendamustine: rebirth of an old drug.
- Resveratrol and cancer prevention.
- Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic Leukemia.
- A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies.
- Adult Burkitt Lymphoma: too soon to declare victory.
- Staging and evaluation of the patient with Lymphoma.
- Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's Lymphoma.
- Bendamustine: a new therapeutic option for hematologic malignancies.
- Classification updates and clinical investigations in indolent non-Hodgkin Lymphoma.
- Monoclonal antibody therapy for B-cell non-Hodgkin's Lymphoma.
- Highlights of the 2008 International Conference on Malignant Lymphoma.
- Recent developments in the treatment of CLL.
- Lenalidomide for the treatment of B-Cell malignancies.
- Most important accomplishments.
- Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL.
Schools
Tufts University
University Of Virginia Hospital
New Eng Med Center Hospital
Conditions Treated
- Acute Leukemia
- Anemia
- Burkitt's Lymphoma
- Coagulation Disorders (incl. Hemophilia)
- View All
Doctors Specialties
- Hematology
Accepted Insurances
Awards
- America's Top Doctors
- CMS Meaningful Use Stage 1 Certification
- America's Top Doctors for Cancer
- Top Doctors:Washington DC Area
- Top Doctors:Washington-Baltimore
- Northern Virginia Magazine
- Fellow (FASCO)
Hospital
-
MedStar Georgetown University Hospital
Drug Facts
| NPI NUMBER | 1992703862 | |
| NPPES Provider LastName | CHESON | |
| NPPES Provider FirstName | BRUCE | |
| NPPES Provider ZIPCode | 200072113 | |
| NPPES Provider State | DC | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 40.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1992703862 |
| Last Name Of The Provider | CHESON |
| First Name Of The Provider | BRUCE |
| View All |
Similar Doctors
|
|
Amy R. Hankin |
|
|
Dr. Yana G. Najjar, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Metin Ozdemirli, MD |
|
|
Dr. Jamie L. Koprivnikar, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Bhaskar V. Kallakury, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Aiwu R. He, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Thomas C. Havell II, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Thomas L. Sacks, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lauren A. Mauro, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jeffrey K. Klotz, MD
This Doctor is OpenDoctor Recommended.
|